Arkis BioSciences Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 11
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $66.1M
Latest Deal Amount

Arkis BioSciences General Information

Description

Developer of neurosurgical devices intended to facilitate minimally invasive surgery. The company's devices advance neurosurgical treatments of intracranial hypertension arising from hydrocephalus, traumatic brain injury and hemorrhagic stroke, enabling surgeons to operate patients with reduces risks and enhance treatment outcome.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 1 Momentum Way
  • PO Box 9815
  • Knoxville, TN 37920
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arkis BioSciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 29-Jul-2019 $66.1M 00.00 000.00 Completed Generating Revenue
4. Early Stage VC 26-Feb-2019 00000 00.00 Completed Startup
3. Early Stage VC (Series A) 09-Mar-2018 00.00 00.000 000.00 Completed Startup
2. Early Stage VC (Series A) 24-Jun-2016 $3.35M $4.35M 00.000 Completed Startup
1. Angel (individual) $1M $1M Completed Startup
To view Arkis BioSciences’s complete valuation and funding history, request access »

Arkis BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00.000
To view Arkis BioSciences’s complete cap table history, request access »

Arkis BioSciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of neurosurgical devices intended to facilitate minimally invasive surgery. The company's devices advance neur
Surgical Devices
Knoxville, TN
11 As of 2018
00.00
00.00 0000-00-00
000000&0 00.00

000 0000

te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
00000000 0000000
Cologne, Germany
000 As of 0000

00000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
00000000 0000000
Clarksville, TN
00 As of 0000
000.00
00 000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arkis BioSciences Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pfm Medical (Germany) Corporation Cologne, Germany 000
000000000 0000000 Private Equity-Backed Clarksville, TN 00 000.00 00 000000
00 0000000000 Venture Capital-Backed Dublin, Ireland 000 00000 0000000000 0 00000
0000000 Corporate Backed or Acquired Rio de Janeiro, Brazil 000 000.00 000000000 000.00
00 000000 Venture Capital-Backed Milpitas, CA 00 00000 00000000000 00000
You’re viewing 5 of 32 competitors. Get the full list »

Arkis BioSciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arkis BioSciences Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Angel Capital Group (Knoxville) Angel Group Minority 000 0000 000000 0
Innova Memphis Venture Capital Minority 000 0000 000000 0
The Lighthouse Fund Angel Group Minority 000 0000 000000 0
To view Arkis BioSciences’s complete investors history, request access »